Literature DB >> 19634593

Predictors of variation in serum IGF1 and IGFBP3 levels in healthy African American and white men.

Cathrine Hoyo1, Janet Grubber, Wendy Demark-Wahnefried, Bruce Lobaugh, Amy S Jeffreys, Steven C Grambow, Jeffrey R Marks, Temitope O Keku, Phillip J Walther, Joellen M Schildkraut.   

Abstract

BACKGROUND: Individual variation in circulating insulinlike growth factor-1 (IGF1) and its major binding protein, insulinlike growth factor binding protein-3 (IGFBP3), have been etiologically linked to several chronic diseases, including some cancers. Factors associated with variation in circulating levels of these peptide hormones remain unclear.
METHODS: Multiple linear regression models were used to determine the extent to which sociodemographic characteristics, lifestyle factors, personal and family history of chronic disease, and common genetic variants, the (CA)n repeat polymorphism in the IGF1 promoter and the IGFBP3-202 A/C polymorphism (rs2854744) predict variation in IGF1 or IGFBP3 serum levels in 33 otherwise healthy African American and 37 white males recruited from Durham Veterans Administration Medical Center.
RESULTS: Predictors of serum IGF1, IGFBP3, and the IGF1:IGFBP3 molar ratio varied by race. In African Americans, 17% and 28% of the variation in serum IGF1 and the IGF1:IGFBP3 molar ratio, were explained by cigarette smoking and carrying the IGF1 (CA)19 repeat allele, respectively. Not carrying at least 1 IGF1 (CA)19 repeat allele and a high body mass index explained 8% and 14%, respectively, of the variation IGFBP3 levels. These factors did not predict variation of these peptides in whites.
CONCLUSION: If successfully replicated in larger studies, these findings would add to recent evidence, suggesting known genetic and lifestyle chronic disease risk factors influence IGF1 and IGFBP3 circulating levels differently in African Americans and whites.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19634593      PMCID: PMC3075867          DOI: 10.1016/s0027-9684(15)30981-0

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  46 in total

1.  Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer.

Authors:  S M Harman; E J Metter; M R Blackman; P K Landis; H B Carter
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

2.  Is there a link between macronutrient intake and prostate cancer?

Authors:  Michael F Leitzmann
Journal:  Nat Clin Pract Oncol       Date:  2005-04

Review 3.  Role of the insulin-like growth factor family in cancer development and progression.

Authors:  H Yu; T Rohan
Journal:  J Natl Cancer Inst       Date:  2000-09-20       Impact factor: 13.506

4.  Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.

Authors:  P Stattin; A Bylund; S Rinaldi; C Biessy; H Déchaud; U H Stenman; L Egevad; E Riboli; G Hallmans; R Kaaks
Journal:  J Natl Cancer Inst       Date:  2000-12-06       Impact factor: 13.506

5.  Impact of nutrients on insulin-like growth factor-I, insulin-like growth factor binding protein-3 and their ratio in African American and white males.

Authors:  Katharine M McGreevy; Brian D Hoel; Stuart R Lipsitz; David G Hoel
Journal:  Public Health Nutr       Date:  2007-01       Impact factor: 4.022

6.  Insulin-like growth factor-1 and binding protein-3 in a 2-year soya intervention among premenopausal women.

Authors:  Gertraud Maskarinec; Yumie Takata; Suzanne P Murphy; Adrian A Franke; Rudolph Kaaks
Journal:  Br J Nutr       Date:  2005-09       Impact factor: 3.718

7.  Lifestyle determinants of serum insulin-like growth-factor-I (IGF-I), C-peptide and hormone binding protein levels in British women.

Authors:  Naomi E Allen; Paul N Appleby; Rudolf Kaaks; Sabina Rinaldi; Gwyneth K Davey; Timothy J Key
Journal:  Cancer Causes Control       Date:  2003-02       Impact factor: 2.506

8.  Insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein (IGFBP)-3 levels in Arab subjects with coronary heart disease.

Authors:  A O Akanji; C G Suresh; R Al-Radwan; H R Fatania
Journal:  Scand J Clin Lab Invest       Date:  2007       Impact factor: 1.713

9.  Grade-specific prostate cancer associations of IGF1 (CA)19 repeats and IGFBP3-202A/C in blacks and whites.

Authors:  Cathrine Hoyo; Janet Grubber; Wendy Demark-Wahnefried; Jeffrey R Marks; Stephen J Freedland; Amy S Jeffreys; Steven C Grambow; Robert M Wenham; Philip J Walther; Joellen M Schildkraut
Journal:  J Natl Med Assoc       Date:  2007-07       Impact factor: 1.798

10.  Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population.

Authors:  Iona Cheng; Katherine DeLellis Henderson; Christopher A Haiman; Laurence N Kolonel; Brian E Henderson; Matthew L Freedman; Loïc Le Marchand
Journal:  J Clin Endocrinol Metab       Date:  2007-06-12       Impact factor: 5.958

View more
  6 in total

1.  Association between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survival.

Authors:  Donghui Li; Motofumi Tanaka; F Charles Brunicardi; William E Fisher; Richard A Gibbs; Marie-Claude Gingras
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

2.  Increase in circulating levels of IGF-1 and IGF-1/IGFBP-3 molar ratio over a decade is associated with colorectal adenomatous polyps.

Authors:  Adelheid Soubry; Dora Il'yasova; Rebecca Sedjo; Frances Wang; Tim Byers; Clifford Rosen; Anatoli Yashin; Svetlana Ukraintseva; Steven Haffner; Ralph D'Agostino
Journal:  Int J Cancer       Date:  2011-09-14       Impact factor: 7.396

3.  Detailed methods of two home-based vegetable gardening intervention trials to improve diet, physical activity, and quality of life in two different populations of cancer survivors.

Authors:  Mallory G Cases; Andrew D Frugé; Jennifer F De Los Santos; Julie L Locher; Alan B Cantor; Kerry P Smith; Tony A Glover; Harvey J Cohen; Michael Daniel; Casey D Morrow; Douglas R Moellering; Wendy Demark-Wahnefried
Journal:  Contemp Clin Trials       Date:  2016-08-23       Impact factor: 2.226

4.  Insulin-like growth factor-1 bioactivity plays a prosurvival role in older participants.

Authors:  Marcello Maggio; Chiara Cattabiani; Fulvio Lauretani; Stefania Bandinelli; Francesca De Vita; Elisabetta Dall'Aglio; Andrea Corsonello; Fabrizia Lattanzio; Giuseppe Paolisso; Luigi Ferrucci; Gian Paolo Ceda
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-05-13       Impact factor: 6.053

5.  Genetic variants in IGF-I, IGF-II, IGFBP-3, and adiponectin genes and colon cancer risk in African Americans and Whites.

Authors:  Temitope O Keku; Adriana Vidal; Shannon Oliver; Catherine Hoyo; Ingrid J Hall; Oluwaseun Omofoye; Maya McDoom; Kendra Worley; Joseph Galanko; Robert S Sandler; Robert Millikan
Journal:  Cancer Causes Control       Date:  2012-05-08       Impact factor: 2.506

6.  Plasma insulin, glucose, IGF-I, IGF-II, and IGFBP-3 and risk of recurrent colorectal adenomas.

Authors:  Melissa Kang; Anne F Peery; Cameron Locklear; Joseph A Galanko; Robert S Sandler; Temitope O Keku
Journal:  J Gastroenterol Hepatol Res       Date:  2013-04-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.